Search Results - cancer

6 Results Sort By:
Application of GARP antibodies and fusion proteins in cancer, inflammatory and immune conditions
Researchers at MUSC have demonstrated that GARP is a novel oncogene due to its cancer-intrinsic roles in promoting invasion and metastasis, as well as its cancer-extrinsic roles in inducing immune tolerance. Administration of a GARP-specific mAb limited metastasis and resulted in an effective cancer therapy in a mouse model of breast cancer (Fig 1)...
Published: 2/1/2017   |   Inventor(s): Zihai Li
Keywords(s): cancer, immune, therapeutic
Category(s): Therapeutic
MUSC Oncology Therapeutics
MUSC Oncology Therapeutics: Liposomal Delivery of Encapsulated Therapeutics to Treat Pediatric Brain Tumorshttp://musc.technologypublisher.com/technology/17463 LSD1 Protein Inhibitors as Epigenetic Modulatorshttp://musc.technologypublisher.com/technology/15182 Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1 (LSD1)http://musc.technologypu...
Published: 2/13/2015   |   Inventor(s):  
Keywords(s): cancer
Category(s): Therapeutic
Therapeutic Approach for Combination Cancer Treatments Using Compounds that Block or Interfere with Thromboxane Signaling Pathways
Inventors at MUSC have developed methods for treatment of cancers, particularly bladder, genitourinary, or pancreatic cancers that involve overexpression of thromboxane receptor β (TP-β). Compounds that block the synthesis of thromboxane A2 or thromboxane A2 signaling pathway alone, or in combination with standard chemotherapy drugs, are ...
Published: 2/13/2015   |   Inventor(s): Omar Moussa, Dennis Watson, Perry Halushka
Keywords(s): cancer, genitourinary
Category(s): Therapeutic
Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1 (LSD1)
Researchers at MUSC have used a ligand-based approach to design and synthesize a series of cyclic peptides that are effective inhibitors of LSD1, and have greater stability to proteolytic degradation than their linear homologues. Cyclic peptide 9 inhibits LSD1 in vitro with a Ki value of 385 nM, and has antitumor activity in MCF-7 and Calu-6 cell ...
Published: 5/13/2014   |   Inventor(s): Patrick Woster, Isuru Kumarasinghe
Keywords(s): cancer
Category(s): Therapeutic
Metabolically Stable, Non-Nephrotoxic Puromycin Analogs as Oncology and Anti-infective Therapeutics
The synthesized compounds are novel analogs of Puromycin that have maintained the same antimicrobial and antitumor activities of the naturally occurring form, but block the formation of toxic by-products. These new analogs may provide promising chemotherapeutic agents that have the same effectiveness of Puromycin without the nephrotoxicity. In prel...
Published: 3/27/2011   |   Inventor(s): Giuseppe Gumina, Roger White
Keywords(s): cancer
Category(s): Therapeutic
Biomarker for the Detection and Monitoring of Bladder Cancer
The inventors have developed a biomarker application based on thromboxane receptor β (TPβ), which identifies patients with various stages of bladder cancers (invasive, superficial, or metastatic). TPβ proteins are overexpressed in common bladder tumor tissue but not normal human cells. Human urine samples of patients positive for var...
Published: 3/27/2011   |   Inventor(s): Omar Moussa, Dennis Watson, Perry Halushka
Keywords(s): cancer, diagnostic, genitourinary
Category(s): Diagnostic
© 2018. All Rights Reserved. Powered by Inteum